Pirisudanol

Pirisudanol
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 2-(dimethylamino)ethyl[5-hydroxy-4-(hydroxymethyl)-6-methyl-3-pyridinyl]methylbutanedioate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.046.887 Edit this at Wikidata
Chemical and physical data
FormulaC16H24N2O6
Molar mass340.376 g·mol−1
3D model (JSmol)
  • CC1=NC=C(C(=C1O)CO)COC(=O)CCC(=O)OCCN(C)C
  • InChI=1S/C16H24N2O6/c1-11-16(22)13(9-19)12(8-17-11)10-24-15(21)5-4-14(20)23-7-6-18(2)3/h8,19,22H,4-7,9-10H2,1-3H3
  • Key:KTOAWCPDBUCJED-UHFFFAOYSA-N
  (verify)

Pirisudanol (Mentis, Menthen, Mentium, Nadex, Nadexen, Nadexon, Pridana, Stivane), also known as pyrisuccideanol, is the succinic acid ester of pyridoxine (a form of vitamin B6) and of deanol (DMAE). It has been used in Europe in the treatment of mild cognitive impairment as well as fatigue and depression.

Synthesis

Pirisudanol is synthesized by the following method:

Cyclic ketal formation between pyridoxine [33605-94-6] HCl: [58-56-0] (1) and acetone resulted in alpha4,3-O-Isopropylidene Pyridoxine [1136-52-3] (2). In the other arm of the synthesis succinic anhydride [108-30-5] (3) is then esterified with Deanol [108-01-0] (4) gives Yakton [10549-59-4] (5). Halogenation of the remaining carboxyl group with thionyl chloride gives PC135056269 (6). In a convergent synthesis, esterification between 2 and 6 gives 7. The last step consists of deblocking the protecting group by hydrolysis with 1% formic acid in ethanol to give the product (8).

Analytical data

(uv, ir, pmr, ms):

See also